Anurogo Dito, Luthfiana Dewi, Anripa Nuralfin, Fauziah Apriliani Ismi, Soleha Maratu, Rahmah Laila, Ratnawati Hana, Wargasetia Teresa Liliana, Pratiwi Sari Eka, Siregar Riswal Nafi, Sholichah Ratis Nour, Maulana Muhammad Sobri, Ikrar Taruna, Chang Yu Hsiang, Qiu Jiantai Timothy
International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.
Faculty of Medicine and Health Sciences, Muhammadiyah University of Makassar, Makassar, South Sulawesi, 90221, Indonesia.
Adv Pharm Bull. 2024 Jul;14(2):314-330. doi: 10.34172/apb.2024.034. Epub 2024 Mar 10.
Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases.
This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology.
Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system's capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells.
While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration.
淋巴瘤是最主要的肿瘤性疾病，分为霍奇金淋巴瘤和非霍奇金淋巴瘤两类。免疫治疗方法已成为对抗淋巴系统恶性肿瘤的重要手段。嵌合抗原受体（CAR）T细胞在化疗耐药的B细胞非霍奇金淋巴瘤病例中显示出有前景的反应。
本综述阐述了CAR-T细胞疗法作为一种免疫治疗手段的进展、用于CAR-T细胞靶向的淋巴瘤抗原的选择以及CAR-T细胞的概念化、合成和应用。此外，它还从计算研究的角度涵盖了CAR-T细胞疗法的优缺点以及CAR-T细胞的未来前景。为了改进人工CAR的设计和功能，需要进行TCR识别研究，随后实施质量监测方法。
多种淋巴瘤抗原适用于CAR-T细胞靶向，如CD19、CD20、CD22、CD30、κ轻链和ROR1。CAR-T细胞疗法的一个显著优点是增强了免疫系统对化疗耐药淋巴瘤患者产生杀瘤活性的能力。然而，它也带来了制造障碍，这些障碍既费力、技术要求高又成本高昂。物理、物理化学和生理限制进一步加剧了用CAR-T细胞治疗实体瘤的挑战。
虽然CAR-T细胞免疫疗法的疗效和安全性仍是深入研究的课题，但这项前沿技术的前景为淋巴瘤治疗管理方法的未来发展提供了有价值的见解。此外，CAR-T细胞疗法可能使患者受益，促使监管机构促进国际合作。
